MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

Search

Axsome Therapeutics Inc

Gesloten

SectorGezondheidszorg

112.26 3.78

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

108.09

Max

114.54

Belangrijke statistieken

By Trading Economics

Inkomsten

15M

-59M

Verkoop

2.7M

121M

Winstmarge

-48.914

Werknemers

712

EBITDA

14M

-57M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+63.57% upside

Dividenden

By Dow Jones

Volgende Winsten

4 aug 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-179M

5.3B

Vorige openingsprijs

108.48

Vorige sluitingsprijs

112.26

Nieuwssentiment

By Acuity

29%

71%

69 / 376 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bearish Evidence

Axsome Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

8 jul 2025, 19:37 UTC

Belangrijke Marktbewegers
Acquisities, Fusies, Overnames

M3-Brigade Shares Fall on Merger With ReserveOne

8 jul 2025, 23:45 UTC

Marktinformatie

Gold Edges Lower, Weighed by Higher Treasury Yields -- Market Talk

8 jul 2025, 23:42 UTC

Marktinformatie

Nikkei May Rise as Yen Weakens -- Market Talk

8 jul 2025, 23:27 UTC

Marktinformatie

Australian REITs Yet to Offer Enough Appeal -- Market Talk

8 jul 2025, 23:27 UTC

Marktinformatie

Global Equities Roundup: Market Talk

8 jul 2025, 23:21 UTC

Marktinformatie

Summerset Bull Lauds Strong 2Q Sales Volumes -- Market Talk

8 jul 2025, 23:21 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

8 jul 2025, 22:29 UTC

Acquisities, Fusies, Overnames

Capricorn to Pay A$1.5 Million in Cash and Shares

8 jul 2025, 22:28 UTC

Acquisities, Fusies, Overnames

Capricorn Metals Enters Binding Agreement to Buy Claw Gold Project

8 jul 2025, 21:58 UTC

Marktinformatie

Kura Sushi Closely Watching U.S. Tariff Negotiations on Asian Goods -- Market Talk

8 jul 2025, 20:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

8 jul 2025, 20:50 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

8 jul 2025, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

8 jul 2025, 20:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

8 jul 2025, 19:53 UTC

Marktinformatie

Copper Posts Biggest One-Day Gain Ever to Hit Record on Tariff Chatter -- Market Talk

8 jul 2025, 19:53 UTC

Marktinformatie

Market Talk Roundup: Latest on U.S. Politics

8 jul 2025, 19:45 UTC

Marktinformatie

Canada Unlikely to Succeed in Bid for Tariff-Free Trade With U.S. -- Market Talk

8 jul 2025, 19:29 UTC

Marktinformatie

U.S. Consumer-Credit Growth Slowed in May -- Market Talk

8 jul 2025, 19:20 UTC

Marktinformatie

U.S. Natural Gas Futures Settle Lower -- Market Talk

8 jul 2025, 19:11 UTC

Marktinformatie

Bank of Canada's Rate Cuts Deliver Muted Relief Along the Curve -- Market Talk

8 jul 2025, 19:01 UTC

Marktinformatie

Oil Futures Gain With Support From Products -- Market Talk

8 jul 2025, 18:49 UTC

Winsten

Hershey Names New CEO, Continuing Leadership Shuffle. The Stock Falls. -- Barrons.com

8 jul 2025, 18:41 UTC

Marktinformatie

Mexico's Inflation Seen Mixed in June -- Market Talk

8 jul 2025, 18:38 UTC

Marktinformatie

Gold Falls as Markets Digest Details of Trump Tariffs -- Market Talk

8 jul 2025, 18:23 UTC

Marktinformatie

Analysts Anticipate Lower Ethanol Inventories -- Market Talk

8 jul 2025, 18:10 UTC

Marktinformatie

Market Talk Roundup: Latest on U.S. Politics

8 jul 2025, 18:10 UTC

Marktinformatie

Freeport-McMoRan Jumps on Trump Tariff Plan for Copper Imports -- Market Talk

8 jul 2025, 17:24 UTC

Marktinformatie

Election, Dollar Seen as Potential Headwinds for Ibovespa -- Market Talk

8 jul 2025, 17:06 UTC

Marktinformatie

KeyCorp and Regional Banks Set for a Catchup -- Market Talk

8 jul 2025, 16:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

Peer Vergelijking

Prijswijziging

Axsome Therapeutics Inc Prognose

Koersdoel

By TipRanks

63.57% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 177.33 USD  63.57%

Hoogste 210 USD

Laagste 148 USD

Gebaseerd op 15 Wall Street-analisten die 12-maands prijsdoelen bieden voor Axsome Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

15 ratings

15

Buy

0

Hold

0

Sell

Technische score

By Trading Central

107.24 / 112.29Steun & Weerstand

Korte Termijn

Weak Bearish Evidence

Gemiddeld Termijn

Neutral Evidence

Lange Termijn

Strong Bullish Evidence

Sentiment

By Acuity

69 / 376 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Axsome Therapeutics Inc

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.